Also, xenograft experiments were done in mice/3 tumor types.
The new pill (AOH1996)💊 works on its own as well as sensitizes to this class of drugs called topoisomerase inhibitors. The latter is also involved in DNA 🧬damage/replication axis.
They also synergize with other drugs like cisplatin which are also considered DNA damaging.
One experiment of note, the drug actually didn't perform superior to one of the old chemotherapy drugs that we seldom use (CPT-11 or commonly called Topotecan).
The light blue line is the old chemo drug. It did better compared to the new pill (shown in red).
34.6%🆚11.5%.
What is my take?
I will just leave the final sentences from the authors themselves: copied/pasted:
"...We acknowledge that positive animal study results do NOT always translate into success in treating cancer patients. Future clinical studies are necessary..."
But I think the bigger issue is that this much hype to a pre-clinical study is not justified. Somewhat premature.
I am all about clinical trials and would I offer this new killer-pill as part of a trial to my patients? Absolutely✅.
Is it ready to cure all? No, unfortunately.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
🧵2️⃣ #GI21 #Cholangiocarcinoma is the poster child of actionable aberrations & truly a 🎯“Target-rich” disease.
We focused on %numbers for aberrations for which there’s either an ✅approved drug, guideline endorsement, #clinicaltrials or even off-label reports/cases.👇🏾
🧵3️⃣ #GI21
We often don’t think of #ctDNA based platforms to be as sensitive for detecting fusions; when present it is real & an actionable finding.
Interestingly we found #FGFR🧬fusions
🩸LIQUID>>TISSUE🔬
💭 maybe because of selection bias. #ctDNA filling the void. #OncoAlert
🆕#ctDNA#liquidbiopsies 🩸🧬
👀 👇🏾at the number of #clinicaltrials cropping up in this space‼️
🇦🇺DYNAMIC-II
🇦🇺DYNAMIC-III
🇺🇸COBRA @NRGonc
🇺🇸BESPOKE
🇺🇸@SU2C
🇯🇵 CIRCULATE
🌎COLUMBIA
🇮🇹🇪🇸PEGASYS
🇬🇧TRACC
🇩🇪CIRCULATE
🇫🇷crEATE
🇩🇰IMPROVE-IT
We have 2🇺🇸studies open. #CRCSM#WorldGI2020
Still miles to go. OS median of 16 months pointing again to the systemic nature of disease. Need to piggyback these local approaches to better systemic. #OncoAlert